REXINOIDS FOR THE TREATMENT OF T CELL LYMPHOMA (TCL): IMPLICATIONS OF THYROID HORMONES (TH) IN BEXAROTENE ANTI-LYMPHOMA ACTIVITY

MARIA MERCEDES DEBERNARDI; FLORENCIA CAYROL, ; JOHANNA DIAZ-ALBUJA; HELENA STERLE; CINTHIA ROSEMBLIT; GRACIELA A. CREMASCHI

Mar del plata

Congreso; Reunión Conjunta SAIC SAI SAFIS 2018; 2018

Sociedad Argentina de Investigación Clínica

Bexarotene (Bex) is a sintetic rexinoid mostly used for the treatmentof cutaneous T-cell lymphoma. Currently, Bex is being studied asalternative therapy for other types of cancer including different subtypesof T cell lymphomas (TCL). TCL are a heterogeneous groupof aggressive lymphoproliferative disorders. Most TCL patients havepoor prognosis, due to the aggressive clinical course and the lack ofhormones are involved in tumor progression. We recently found thatare required for proliferation of TCL. Paradoxically, Bex is associat-to evaluate Bex action on different subtypes of TCL, distinct fromof this rexinoid. LL1 (immature) and, OCI-Ly12, OCI-Ly13.2 and MAC2a (mature).Ly13.2 cells Bex activity in the presence or absence of physiologicalconcentrations of TH. After treatment Bex decreased viability andinduce apoptosis in all cell lines, but in the presence of TH bothmay help to improve the response to treatment of TCL patients.